Detalhe da pesquisa
1.
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.
Haematologica
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813708
2.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38060001
3.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137397
4.
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Eur J Haematol
; 107(4): 436-448, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34139044
5.
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.
Haematologica
; 104(5): 947-954, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442723
6.
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.
Am J Hematol
; 95(1): E1-E3, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31588594
7.
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).
Br J Haematol
; 186(5): e123-e126, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31106402
8.
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
Haematologica
; 103(9): e392-e394, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29622658
9.
Incidence of blast phase in myelofibrosis according to anemia severity.
EJHaem
; 4(3): 679-689, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37601878
10.
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
NEJM Evid
; 2(6): EVIDoa2200335, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38320126
11.
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Blood
; 115(9): 1703-8, 2010 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-20008785
12.
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Blood Adv
; 6(6): 1855-1864, 2022 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35130339
13.
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Leukemia
; 36(10): 2453-2460, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36042316
14.
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Lancet Haematol
; 8(3): e175-e184, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476571
15.
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
Cancer Med
; 8(9): 4089-4092, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31173472
16.
Fluid loss does not explain coagulation activation during air travel.
Thromb Haemost
; 99(6): 1053-9, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18521508
17.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Blood Adv
; 3(21): 3196-3200, 2019 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31698448
18.
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
Blood Cancer J
; 8(10): 89, 2018 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291232
19.
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.
Leuk Res
; 69: 100-102, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29734070
20.
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.
Blood
; 111(7): 3383-7, 2008 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18187660